COMPOSITION : Each Tablet contains :-
Pantoprazole 40 mg
Pantoprazole belongs to a class of drugs known as proton pump inhibitors. It acts by reducing the amount of acid produced in the stomach.
Pantoprazole is a substituted benzimidazole indicated for the short-term treatment (up to 16 weeks) in the healing and symptomatic relief of erosive esophagitis. Pantoprazole is a proton pump inhibitor (PPI) that suppresses the final step in gastric acid production.
Pantoprazole is well absorbed. It undergoes little first-pass metabolism resulting in an absolute bioavailability of approximately 77%.
Protein binding : 98%
Pantoprazole is extensively metabolized in the liver through the cytochrome P450 (CYP) system. The main metabolic pathway is demethylation, by CYP2C19, with subsequent sulfation; other metabolic pathways include oxidation by CYP3A4. There is no evidence that any of the pantoprazole metabolites have significant pharmacologic activity.
After administration of a single intravenous dose of 14C-labeled pantoprazole to healthy, normal metabolizer subjects, approximately 71% of the dose was excreted in the urine with 18% excreted in the feces through biliary excretion.
INDICATION : Gastro- oesophageal reflux disease
DOSAGE : As directed by the physician
Vertigo, Fracture of the hip, Wrist or spine, Pruritis, Pyrexia, Diarrhea, Blurred vision, Dizzines